This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fan, T. Articles by Jiang, F. Search for Related Content PubMed PubMed Citation Articles by Fan, T. Articles by Jiang, F.

Up-regulation of 14-3-3 in Lung Cancer and Its Implication as Prognostic and Therapeutic Target

Departments of ¹ Pathology, ² Surgery, and ³ Medicine, and ⁴ Division of Biostatistics of The University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland; ⁵ Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and ⁶ Department of Carcinogenesis, Science Park-Research Division, The University of Texas M. D. Anderson Cancer Center, Smithville, Texas

Requests for reprints: Feng Jiang, Department of Pathology, The University of Maryland School of Medicine, 10 South Pine Street, MSTF 7th Floor, Baltimore, MD 21201-1192. Phone: 410-706-7056; Fax: 410-706-8414; E-mail: fjiang{at}som.umaryland.edu.

A functional genomic approach integrating microarray and proteomic analyses done in our laboratory has identified 14-3-3 as a putative oncogene whose activation was common and driven by its genomic amplification in lung adenocarcinomas. 14-3-3 is believed to function in cell signaling, cycle control, and apoptotic death. Following our initial finding, here, we analyzed its expression in lung tumor tissues obtained from 205 patients with various histologic and stage non–small cell lung cancers (NSCLC) using immunohistochemistry and then explored the effects of specific suppression of the gene in vitro and in a xenograft model using small interfering RNA. The increased 14-3-3 expression was positively correlated with a more advanced pathologic stage and grade of NSCLCs (P = 0.001 and P = 0.006, respectively) and was associated with overall and cancer-specific survival rates of the patients (P = 0.022 and P = 0.018, respectively). Down-regulation of 14-3-3 in lung cancer cells led to a dose-dependent increased sensitivity to cisplatin-induced cell death, which was associated with the inhibition of cell proliferation and increased G₂-M arrest and apoptosis. The result was further confirmed in the animal model, which showed that the A549 lung cancer cells with reduced 14-3-3 grew significantly slower than the wild-type A549 cells after cisplatin treatment (P = 0.008). Our results suggest that 14-3-3 is a potential target for developing a prognostic biomarker and therapeutics that can enhance the antitumor activity of cisplatin for NSCLC. [Cancer Res 2007;67(16):7901–6]

This article has been cited by other articles:

				Z. Li, J. Zhao, Y. Du, H. R. Park, S.-Y. Sun, L. Bernal-Mizrachi, A. Aitken, F. R. Khuri, and H. Fu Down-regulation of 14-3-3{zeta} suppresses anchorage-independent growth of lung cancer cells through anoikis activation PNAS, January 8, 2008; 105(1): 162 - 167. [Abstract] [Full Text] [PDF]